Dr. Nacev is a laboratory-based physician scientist. The scientific goal of the Nacev Lab is to understand how cancer-associated genetic alterations in chromatin regulators promote cancer and to leverage this understanding to advance new therapeutic approaches in the clinic. Specifically, we model these events and study how the epigenome is dysregulated to alter transcriptional and developmental programs important for cancer growth and oncogenic behavior. To do so, we employ diverse tools including genetics, chemical approaches, and epigenomic approaches.
Dr. Nacev is a medical oncologist with a specialization in caring for adult patients with sarcomas. Dr. Nacev collaborates with clinical trialists to design studies and correlates within his area of research focus, cancer epigenetics.
- AB, University of Chicago, 2004
- MD, PhD, Johns Hopkins School of Medicine, 2013
- Residency, Internal Medicine, Osler Medical Residency, The Johns Hopkins Hospital, 2016
- Fellowship, Medical Oncology, Memorial Sloan Kettering Cancer Center, 2019
Education & Training
- Alpha Omega Alpha, 2016
- Medical Oncology Co-Chief Fellow, Memorial Sloan Kettering, 2017-2018
- John Mendelsohn Housestaff Teaching Award, Memorial Sloan Kettering, 2018
- Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award, 2019
- QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research, 2019
- National Cancer Institute, Mentored Clinical Scientist Research Career Development Award (K08), 2019
- MSKCC SPORE in Soft Tissue Sarcoma Career Enhancement Program (CEP), 2020
- Connective Tissue Oncology Society (CTOS) Basic Science Research Award, 2020
